Search

This book will give an up-to-date and thorough exposition of the state of the art of concepts, design, and recent advances in nanobiotechnology-based strategies for cancer Immunotherapy, and their current and clinical status. Nanobiotechnology-based Targeted therapies and Immunotherapy have been added to the effective oncologic treatment and have become increasingly popular in oncology. It is intended to enable the researchers to prepare a variety of Nanobiotechnology-based strategies, investigate their properties, and discover their uses and applications in cancer immunotherapy. The novelty of the approach is to address an existing need to understand exhaustively the potential of the nanotechnology-based approaches, including targeted and smartly designed therapies, that deliver loaded immunoreactive (s) into the body at predefined sites. The book will also discuss the patents related to cancer immunotherapy. Because of the versatility and wide range of properties, nanobiotechnology-based systems are extensively used in cancer immunotherapy. The task of obtaining a versatile candidate in immune component(s) delivery seems to be intricated, as it has to surpass several vigorous clinical barriers. As a result, many scientists rely on nanobiotechnology-based approaches, which have already been approved and well-established. Over the years, extensive research has been undertaken on the delivery of immunoreactive(s) using nanotechnology-based delivery systems. With advancements in nanobiotechnology, more needs are realized to develop nanoengineered/smart delivery systems with even more convoluted properties. Currently, research is mainly focused on nanoengineered systems, which can perform one or more of the desired functions. The proposed book summarizes the basic principles and research supporting cancer immunotherapy clinical translation contains nanobiotechnology-based treatment strategies for all immunotherapy classes and agents, including cell-based therapies, monoclonal antibodies, cytokine therapies, checkpoint inhibitors, oncolytic viruses, adjuvant approaches, treatment combinations Includes information on all FDA-approved immunotherapies, for individual cancer types, including melanoma and other skin cancers, lung cancers, gastrointestinal cancers, hematologic cancers, genitourinary cancers, head and neck cancers, sarcomas, brain cancers, and breast cancer etc. Also explains the regulatory aspects behind the development and approval of immunotherapy drugs.

Hepatobiliary cancers, including hepatocellular carcinoma and biliary tract cancers, have high rate of mortality and low survival rate. The third volume of the “Interdisciplinary Cancer Research” series, entitled “Hepatobiliary Cancers: An Interdisciplinary Approach” publishes comprehensive volumes on mechanisms of hepatobiliary cancers and therapeutic modalities and presents the most updated and peer-reviewed chapters on hepatobiliary cancers. This interdisciplinary series is of special value to researchers working on cell biology, immunology, biochemistry, genetics, and practitioners working on oncology and gastroenterology. This is the main concept of Cancer Immunology Project (CIP), which is a part of Universal Scientific Education and Research Network (USERN). This interdisciplinary book will be of special value for researchers, oncologists, and gastroenterologists who wish to extend their knowledge on hepatobiliary cancers.

This book now published in its fully updated second edition comprehensively summarizes the current state of knowledge on malignancies of the gastrointestinal tract and highlights the latest efforts in multimodality treatment options before and after surgery, important ongoing trials as well as future areas of investigation. Dedicated organ-based chapters evaluate current treatments and management and provide information on incidence, etiology and biological characteristics. The state of the art in the radiologic and endoscopic staging of gastrointestinal malignancies is described, and guidance is offered on the role of interventional radiology and interventional gastroenterology in the treatment of these challenging tumors. In addition, the book explores novel and evolving treatments, including Immunotherapy, personalized systemic therapy and minimally invasive surgical and radiology techniques, and addresses patient-reported outcomes and survivorship challenges. It will be of benefit to all surgeons, oncologists and other specialists who treat these malignancies, as well as to trainees looking to increase their understanding of the field.

Survival of patients with metastatic cancer has increased over the past two decades as a result of a progressive improvement of regional and systemic therapies. However, oncologists'estimates of patients'predicted overall survival in metastatic cancer are imprecise. The purpose of this book is to systematize the evidence regarding the prognostic factors of metastatic gastrointestinal tumors, separating the findings with the highest level of evidence among those available for each disease by selecting studies with the highest scientific evidence level.

Designed for quick, everyday reference, Handbook of Targeted Cancer Therapy and Immunotherapy, 3rd Edition, includes clinical trial results of more than 250 state-of-the-art targeted therapy and immunotherapy agents, providing a practical, intuitive, colorful overview of this rapidly advancing field. Comprehensive yet concise, this easy-access resource by Drs. Daniel D. Karp, Gerald S. Falchook, and JoAnn D. Lim, helps you navigate through the newest research reports and apply the most recent discoveries as they pertain to specific tumor types, actionable molecular targets, and clinical performance of investigational targeted agents and combinations of agents. This handbook presents information distilled by dozens of translational research clinicians and other healthcare experts with hundreds of years of cumulative experience in the revolutionary area of genomically based precision oncology.

HOLLAND-FREI CANCER MEDICINE The latest edition of the gold-standard in cancer science and clinical oncology references In the newly revised Tenth Edition of Holland-Frei Cancer Medicine, a team of distinguished researchers and practitioners delivers a comprehensive and up-to-date discussion of cancer science and clinical oncology practice. The book contains timely and indispensable information on epidemiology, etiology, cancer biology, immunology, prevention, screening, clinical presentation, pathology, imaging, and therapy. Grounded in a fundamental understanding of cancer biology, Holland-Frei Cancer Medicine combines scientific principles with clinical practice. It contains hundreds of full-color illustrations and photographs, tables, graphs, and algorithms that complement and enhance the complex topics discussed within the book. This book is an invaluable clinical tool that provides readers with overview boxes, additional references, and other pedagogic features designed to make the content easy to access and comprehend. Readers will also find: A translational and integrated approach throughout the book that combines cancer biology with cancer management A strong emphasis on multidisciplinary, research-driven patient care that improves outcomes and allows for the optimal use of all clinically appropriate therapies Discussions of the most current personalized cancer care, including molecular diagnostics and therapeutics Perfect for medical oncologists, radiation oncologists, and internists, Holland-Frei Cancer Medicine, Tenth Edition will also earn a place in the libraries of allied health professionals involved in the treatment of cancer patients. This book is published in collaboration with the American Association for Cancer Research: https://www.aacr.org/

Designed for quick, everyday reference, Handbook of Targeted Cancer Therapy and Immunotherapy: Gastrointestinal Cancer provides a practical overview of this rapidly advancing field. Comprehensive yet concise, this easy-access resource by Dr. Milind Javle of MD Anderson Cancer Center and Dr. Mitesh J. Board of Mayo Clinic helps you filter and apply the most recent discoveries as they pertain to specific tumor types, actionable molecular targets, and clinical performance of investigational targeted agents and combinations of agents.

Treatment Landscape of Targeted Therapies in Oncology: Challenges and Opportunities provides up-to-date knowledge on antitumor-targeted therapies and immunotherapy. The book's chapters are written by researchers dynamically working/focusing on cancer treatment. The content is designed to help those who are new to the field (beginners) and various specialized scientists and researchers involved in cancer research. For decades, the hallmark of cancer treatment has been conventional chemotherapy. But with the rapid increase in our understanding of the immune system, more and more small molecules, peptides, recombinant antibodies, vaccines and cellular therapeutic modalities are being applied to manipulate the immune response for cancer treatment. - Covers basic concepts and updated knowledge of the latest anticancer drugs - Brings comprehensive understanding of the treatment of cancer in context of immunotherapy and targeted therapy - Introduces the latest drugs and advancements in the treatment of cancer - Includes detailed diagrams to give insight to the mechanisms of action

This book provides an overview of the available evidence surrounding immunotherapy in gastrointestinal cancers, and discusses its future place in clinical practice.Immunotherapy has celebrated some astonishing therapeutic successes in a variety of cancer types and is becoming increasingly relevant in daily clinical practice. Currently, the predominant class of immunotherapeutic drugs is the so-called checkpoint inhibitors, which disengage the physiological brakes on the immune system, enabling a more effective anti-cancer immune response. Malignancies of the gastrointestinal tract, which account for the majority of cancer cases worldwide, are a major cause of morbidity and mortality, creating an urgent need for more effective therapies. A large number of clinical trials have evaluated the efficacy of cancer immunotherapy in gastrointestinal malignancies and demonstrated its potential in certain subsets of patients. This book will appeal to a wide readership, including oncologists, health care professionals in general and biomedical scientists.

This book illustrates the significance of probiotics and prebiotics for the management of various types of cancers. The up-to-date chapters provide recent information about the effect of anticancer treatment approaches on gut microbiota, the correlation between ROS and synbiotics for effective cancer treatment, and the influence of synbiotics on inflammation and immune microenvironment for cancer treatment. It also describes the regulatory issues about synbiotics in the management of cancer. This book is an essential resource for scientists working in the field of cancer, pharmaceutical & clinical sciences, and cancer clinicians. This book is also very useful for undergraduate and postgraduate students of Pharmacy and Biotechnology and medical researchers, mainly working in microbiology, immunology, and cancer biology.

Gastrointestinal cancer is one of the most prevalent causes of cancer-related deaths in the world. Recent research demonstrates that phytochemicals are critical in preventing and managing gastrointestinal cancer. The increased intake of phytochemicals could reduce the risk of cancer by inhibiting cancer cell proliferation, inducing apoptosis and autophagy, and suppressing angiogenesis as well as cancer cell metastasis. These mechanisms are also known to counter Helicobacter pylori infection and modulate gut microbiota. There is preliminary data suggesting that daily supplementation with high doses of certain vitamins combined with conventional therapeutic agents may enhance their growth inhibitory effects on tumor cells and protect normal tissues against some of their toxic effects.This book attempts to fill gaps on the role of phytonutrients in the treatment of cancer in the gastrointestinal tract (GIT). It discusses the action of individual vitamins on cellular and molecular parameters and describes how vitamins inhibit protein kinase C activity, increase the production of certain growth factors, and modulate the expression of a number of oncogenes.The book is divided into 2 parts. The first part summarizes the pathophysiology of GIT cancers and introduces readers to anticancer phytonutrients. A chapter on the status of FDA approved nutraceuticals rounds up this section. The second part of the book provides a systematic review on the different plant derived chemicals that can be used to treat GIT cancer. Each chapter in this section focuses on a specific type of phytochemical agent and its molecular mechanisms relevant to the disease.This book will give the reader a holistic view of gastrointestinal cancer treatment and the value of natural compounds in developing functional food and drugs for preventive medicine.

Integrating the reflections of a practicing clinical pharmacist who specializes in hematology and oncology, this book illuminates some of the most fundamental yet fascinating aspects of a broad range of solid and blood cancers, their novel drug therapies, and strategies to advance oncology pharmacy practice. By emphasizing key concepts rather than a comprehensive review, it provides a clear introduction to oncology principles, making it easier for clinicians and students alike to understand pathophysiology, pharmacology and supportive care issues.

This comprehensive book provides an overview of cancer therapeutics and covers different innovative treatment approaches for cancer. The initial chapter gives a detailed overview on cancer progression and disease diagnostics. The following chapters focus on different cancer treatment approaches, such as chemotherapy, radiotherapy, hormonal therapy, immunotherapy, nutritional assessments, targeted therapy and Nano therapeutics. It also highlights the importance of cancer genomics, disease advancement, personalized medicine and psychological support for cancer patients. Emphasis is also given to the many challenges in the area of designing cancer treatment and designing clinical trials. The complete book also presents cancer management with different cancer treatment modalities, including pharmacogenomics and drug reactions. This is a unique and comprehensive piece of work that not only highlights the disease treatment modalities but also focuses on many challenges in the area of designing cancer treatment and even in designing clinical trials.The contributing authors are experts in this field of cancer treatment. By familiarizing readers with the latest developments in this complex field, the book offers a valuable resource for clinicians. Researchers and medical students will also benefit from this comprehensive text.

Designed for quick, everyday reference, Handbook of Targeted Cancer Therapy and Immunotherapy: Breast Cancer provides a practical overview of this rapidly advancing field. Comprehensive yet concise, this easy-access resource by Drs. Senthil Damodaran and Debu Tripathy of MD Anderson Cancer Center helps you filter and apply the most recent discoveries as they pertain to specific tumor types, actionable molecular targets, and clinical performance of approved or investigational targeted agents and combinations of agents.

This book thoroughly illustrates the designed and tailored medical approaches for tumors of the female reproductive organ. The chapters explore different cancer species such as ovarian cancer, endometrial cancer, cervical cancer, etc. Various treatment modalities such as immunotherapy and histotype-specific treatment are delivered, and it offers a chapter on how genome-wide analysis contributes to personalized treatment. It is essential to understand this concept because many molecular target drugs and the prevalence of genome-based analysis in clinical settings have enabled us to introduce valid precision medicine in the field of gynecologic oncology. Chapters explain the stream of transition from conventional standardized treatment to personalized treatment and address future perspectives.Personalization Gynecologic Oncology is a well-designed source for beginning to advanced oncologists, gynecologists, geneticists, genetic counselors, and nurses. Offering the latest treatment strategies, the Editor hopes the ideas presented here will be a foundation for further development in the field.

Single best answers to 500+ questions covering all of the key exam topics Perfect preparation and practice for the medical oncology SCE and a valuable tool for the FRCR (Oncology) and ESMO exams Produced in partnership with the Association of Cancer Physicians (ACP) Written by senior trainees and consultants and verified by experienced medical oncology consultants in the style of the specialty certificate exam, this collection of 500 single best answers offers an ideal preparation for success. The aim of 500 SBAs for the Medical Oncology Specialty Certificate Exam is to provide an important evidence-based resource for trainees and non-trainees in preparation for the SCE in Medical Oncology. The practice questions enable learners to assess their own knowledge and identify gaps for further learning. Single-best answer (SBA) questions are accompanied with a description of the answer that highlights important trial data, NICE/other national guidelines and resources. The question number and layout closely mirrors that of the SCE blueprint. Topics covered follow the blueprint of the exam closely, and include: Scientific basis of malignancy, Systemic anti-cancer therapy, Acute oncology, Supportive therapies and palliative care, Breast cancer, Upper GI cancer, Colorectal and anal cancer, Lung and thoracic cancer, Gynaecological cancers, Urological and germ cell cancers, Haematological cancers, Skin cancer, Sarcoma. Less common cancers (Head and neck, CNS cancers, Endocrine), Carcinoma of unknown primary, Professional skills and ethics. Make this book the last thing you use before you take the exam.

Quality of life is an important outcome when treating a cancer patient. Research is vast on the role of quality of life on patients'general wellbeing, responsiveness to treatment, and even mortality. On the other hand, there are several methodological considerations when planning to measure and assess quality of life in cancer patients. This handbook – with authorship that is diverse in terms of perspectives, countries, and fields – aims to fill a gap in the available literature and responds to a number of questions in its 26 chapters:What is quality of life and health-related quality of life and why are they important?How is quality of life assessed?What are the theoretical and methodological considerations when using quality of life outcomes in cancer research?How is quality of life useful in routine clinical care?How is quality of life impacting different cancer populations in terms of site of the cancer, age, gender, and context?Handbook of Quality of Life in Cancer is a learning and consulting tool that can be used by a diverse audience. It is an essential resource for researchers who wish to use quality of life assessment tools in clinical trials or other types of studies; clinicians who want to develop their understanding of how they can utilize quality of life and how it is important for the patients they care for; and commissioners who wish to see why quality of life may impact population health and health system costs. Students in diverse fields of study (medicine, nursing, psychology, social work, medical sociology, population health, epidemiology, and medical statistics, among others) also would benefit from using the handbook for their studies and for their continuing professional development.

This book illustrates the basics and underlying molecular machinery of cancer cells and biochemical assays that detect the type and stage of cancer through cell signaling biomarkers. It starts with a brief introduction to cancer biomarkers and addresses technologies for identifying and validating cancer biomarkers, biomarkers for cancer drug development, prognostic and diagnostic biomarkers, and microbiome as cancer biomarkers. It reviews predictive biomarkers for anticancer drugs, biomarkers in cancer survival and drug resistance, biomarkers in tumor recurrence and metastasis, the role of the biomarker in immunotherapy and personalized medicine, and the development of a novel cancer biomarker. Finally, this book also underpins the role of nanotechnology in the use and detection of cancer biomarkers for enhanced sensitivity and specificity. Lastly, it discusses the challenges with biomarkers in cancer drug discovery and development. This volume is an indispensable tool for researchers working in the field of cancer and also for clinical oncologists.

The standard-setting text in oncology for 40 years, DeVita, Hellman and Rosenberg's Cancer: Principles and Practice of Oncology, 12th Edition, provides authoritative guidance and strategies for managing every type of cancer by stage and presentation. Drs. Vincent T. DeVita, Jr., Theodore S. Lawrence, and Steven A. Rosenberg oversee an outstanding team of expert contributing authors who keep you up to date and fully informed in this fast-changing field. This award-winning reference is also continually updated on Health Library and VitalSource platforms for the life of the edition.

Now, it its second edition, this book summarizes the role of immune cells in tumor suppression and progression. It describes in detail why tumor cells can survive and spread in spite of the antitumor response of immune cells. Since immunotherapy is an attractive approach to cancer therapy, this book also provides information on the two main strategies: monoclonal antibodies and adaptive T cell immunotherapy, with a focus on recent human clinical trials. A newly added chapter also focuses on the role of Natural Killer cells in tumor progression. The book provides a state-of-the-art, comprehensive overview of immune cells in cancer and is an indispensable resource for researchers and practitioners working or lecturing in the field of cancer research and immunology.

Thoroughly updated to reflect major advances in the field of immuno-oncology, this second edition of Cancer Immunotherapy Principles and Practice, from the Society for Immunotherapy of Cancer (SITC), remains the definitive resource for information on tumor immunology and cancer immunotherapy treatments. An essential reference for both novice and experienced cancer researchers, oncologists, and related practitioners alike, the book not only guides readers through the fundamental scientific principles of the field all the way to translational and practical clinical applications for treating and managing oncologic disease, but also provides a comprehensive understanding of the regulatory processes that support the safe and effective delivery of immunotherapy to patients with cancer. The expanded and updated second edition now spans 68 chapters, including 12 new chapters, covering major topics and innovations that have shaped the rapid development of immunotherapy and its ascension into the standard of care as first-line treatment for a growing number of disease settings. New to this edition are chapters with deeper insight into our understanding of cancer genomics and determinants of response, immunogenic cell death, cancer and stromal cell-intrinsic pathways of immune resistance, cancer immune exclusion, adoptive cell therapy, metabolomics, tumor mutation burden, immunotherapy in combination with radiation therapy, synthetic biology, and more. Complete with detailed illustrations, tables, and key points for targeted reference, Cancer Immunotherapy Principles and Practice, Second Edition is the most comprehensive and authoritative resource for scientists and clinicians looking to expand their knowledge base of this dynamic field. Key Features: Offers key insights and perspectives on cancer immunology and immunotherapy treatments from renowned experts in the field Covers the basic principles and science behind cancer immunotherapy and tumor immunology Includes treatment strategies for a vast array of available immunotherapy classes and agents, such as cytokine therapies, oncolytic viruses, cancer vaccines, CAR T therapies, and combination immunotherapies Provides essential information on FDA-approved immunotherapies, including clinical management and outcome data related to response rates, risks, and toxicities Discusses special considerations for immunotherapy in the context of specific disease settings, including skin cancers, genitourinary cancers, gastrointestinal cancers, hepatocellular carcinomas, gynecologic malignancies, breast cancers, lung cancers, head and neck cancers, brain tumors, sarcomas, pediatric cancers, and treatments combined with radiation therapy Clarifies the complex regulatory aspects behind the development and approval of immunotherapy drugs

This new edition provides the essential clinical guidance both for those embarking upon a career in palliative medicine and for those already established in the field. A team of international experts here distil what every practitioner needs to know into a practical and reliable resource.

This book reviews current immunotherapeutic strategies for gastrointestinal (GI) malignancies, including immune composition, immune checkpoint inhibitors, cell therapy, and peptide vaccines used to protect against esophageal, gastric, hepato-biliary, pancreatic and colorectal cancers. It also discusses the current challenges of using immunotherapy for the treatment of gastrointestinal malignancies. The book reviews highly sensitive and specific immunomarkers for the detection of GI malignancies, and examines therapeutic vaccines and the major cytokines involved in GI immunotherapy, as well as their basic biology and clinical applications. In closing, the book explores various aspects of computational biology for the detection and treatment of GI malignancies.

This book is a comprehensive reference work on the multidisciplinary team (MDT) management of colorectal cancer (CRC) patients that will meet the needs of all members of CRC MDTs and those training in the field. Important, up-to-date knowledge is provided on organization of MDTs, early intervention, surgery, oncology, imaging, pathology, and palliation, with special focus on controversies. This second edition has been thoroughly revised. It includes an entirely new section on the principles of treatment of significant polyps and early cancers and a total of 14 new chapters, including one on the early integration of palliative care. Every effort has been made to ensure that each specialty-specific chapter will be approachable for all team members, thereby facilitating an effective interdisciplinary approach to teamwork. The authors are leading European doctors and scientists who have influenced the development of the MDT concept as well as other aspects of individualized treatment ofCRC patients.

This book provides essential information on recent advances in molecular genetics, epidemiology, translational research, and the latest results of clinical trials on mesothelioma. Significant progress has been made in understanding mesothelioma biology, and in developing new therapies for this refractory tumor, malignant pleural mesothelioma (MPM). Not only does this volume summarize the latest research-based data on the disease; it also shares insights into future research directions.The book consists of 5 themed sections on: epidemiology, pathogenesis, screening and early detection, molecular genetics, and clinical aspects and management. Several chapters focus on new trends in the field, e.g. immune therapy and identification of biomarkers, molecular oncogenesis including genetic susceptibility, and molecular diagnostic pathology. The book also highlights new cancer treatment approaches, such as immunotherapy based on immune checkpoint inhibitors, which has meanta paradigm shift in other types of cancer, and given some hope to MPM patients. In turn, it discusses recent molecular pathological studies on mesothelioma, which claim to offer more accurate classifications than traditional morphology and immunohistochemistry-based approaches. All of these cutting-edge analyses provide the basis for a closing discussion on future developments and research directions.Malignant Pleural Mesothelioma - Advances in Pathogenesis, Diagnosis, and Treatments has been edited and authored by respected researchers and will be of interest to medical, surgical and radiation oncologists; pulmonologists; pathologists and basic researchers alike. Since the disease represents a significant diagnostic and therapeutic challenge, scientists and clinicians from learners to experts, as well as fellows in training in these subspecialties, will value this book.

Evidence-based, superbly illustrated, and easy to read, Berek & Hacker's Gynecologic Oncology, Seventh Edition, remains your reference of choice for authoritative information on every aspect of gynecologic malignancies. Templated chapters provide quick access to guidance on everything from general principles through diagnosis and medical and surgical management. This fully revised edition offers the practical, state-of-the-art coverage you need when caring for women with preinvasive disease; ovarian, breast, uterine, cervical, vulvar, and vaginal cancers; and gestational trophoblastic disease.

This book presents a compact overview of the history, evolution and fascinating novel applications of antibodies for the treatment of cancer, leading the reader step by step to the latest advances. Interesting anecdotes, together with self-explanatory and clearly structured figures with a humorous touch, facilitate the reader's understanding of this complex topic. Clinical cases round out the book, making it a valuable aid for professionals in their everyday practice. The growing importance of the topics covered here was highlighted by the joint award of the 2018 Nobel Prize in Chemistry to Frances H. Arnold (directed evolution of enzymes), George P. Smith (phage display of peptides) and Sir Gregory P. Winter (phage display of antibodies). Furthermore, the 2018 Nobel Prize in Physiology or Medicine was awarded to James P. Allison and Tasuku Honjo for their discovery of cancer therapy by inhibition of negative immune regulation. Many of the antibodies that are now being brought to market target precisely these immune checkpoint modulators. The book addresses a broad readership, ranging from professionals and experts in the field to residents and medical students.

Early recognition and management of adverse effects of cancer treatments are essential for optimal care of patients with cancer, and drastically different approaches are required for different physiologic reactions. Handbook of Cancer Treatment-Related Symptoms and Toxicities is a focused, one-stop resource that enables clinicians to quickly find up-to-date, reliable information needed at the point of care. The high-yield approach prioritizes the most common toxicities associated with cancer treatment, and concise, templated chapters offer fast access to information needed in day-to-day practice. - Presents a user-friendly overview of cancer treatment-related symptoms and toxicities management in a practical, easy-to-use format, allowing you to quickly find information in one convenient, concise resource. - Covers systemic and radiation therapies, including chemotherapy, immunotherapy, targeted therapies, and radiation therapy, detailing symptoms of each toxicity to confirm your diagnosis. - Overviews pharmacologic and non-pharmacologic approaches to symptom management. - Offers recommendations for mitigating toxicities in high-risk patients. - Discusses key topics such as management of infusion reactions, when the need for biopsy is warranted, and the unique challenges posed by novel immunotherapies.

This book provides a comprehensive overview of the fast-evolving subject of clinical application of cancer therapeutic biomarkers. The second edition captures significant progress of cancer immunotherapy and emphasizes the genetic basis for selective cancer treatment. It covers an in-depth insight on biomarkers across a broad area of cancer research and oncology with a wealth of integrated genetic and molecular information about specific therapies by a multidisciplinary team of internationally recognized experts. Each chapter focuses on a class of targeted, immunologic, or chemotherapy agents and their companion biomarkers that predict response, benefit or resistance, and severe adverse event. The book will serve as a handbook for health professionals and scientists on the current applicable biomarkers in the management of cancer. The vision into the systemic classification and statistical consideration of therapeutic biomarkers summarized by the book editors and chapter authors will help advance precision medicine—a precisely tailored cancer treatment strategy for cancer patient care.

Colorectal cancer (CRC) is a major global health challenge as the third leading cause for cancer related mortalities worldwide. Despite advances in therapeutic strategies, the five-year survival rate for CRC patients has remained the same over time due to the fact that patients are often diagnosed in advanced metastatic stages. Drug resistance is another common reason for poor prognosis. Researchers are now developing advanced therapeutic strategies such as immunotherapy, targeted therapy, and combination nanotechnology for drug delivery. In addition, the identification of new biomarkers will potentiate early stage diagnosis.This book is the first of three volumes on recent developments in colorectal diagnosis and therapy. Each volume can be read on its own, or together. Each volume focuses on different novel therapeutic advances, biomarkers, and identifies therapeutic targets for treatment. Written by leading international experts in the field, coveragealso addresses the role of diet habits and lifestyle in reducing gastrointestinal disorders and incidence of CRC. Chapters discuss current and future diagnostic and therapeutic options for colorectal cancer patients, focusing on immunotherapeutic, nanomedicine, biomarkers, and dietary factors for the effective management of colon cancer.

The second edition of this very successful book documents the latest progress in the prevention, diagnosis and treatment of esophageal cancer and includes additional sections covering novel targeted therapeutic approaches, immunotherapy and palliative and nutritional support for patients. Furthermore, the sections covering epidemiology, molecular biology, pathology, staging and radiologic and endoscopic assessments have been thoroughly updated and expanded. The principles of surgical resection, radiation therapy and systemic therapy are reviewed and attention is paid to the multidisciplinary approaches to the management of early stage cervical, thoracic, distal and junctional tumors. Updated information is also provided on the treatment of metastatic and recurrent disease as well as approaches that may impact future care, such as chemoprevention. Esophageal Cancer: Prevention, Diagnosis and Therapy will assist specialists from various disciplines, including surgery,radiation therapy, gastroenterology, medical oncology and palliative medicine, in delivering optimal, up-to-date care to the benefit of patients.

This book reviews the potential of next-generation sequencing (NGS) in research on and management of colorectal cancer (CRC), a leading cause of death worldwide and one of the most biologically and clinically heterogeneous cancers. It critically discusses findings from recent large-scale studies, clinical trials and meta-analyses and offers an introduction to the management of CRC in the era of precision medicine. In CRC, dozens of driver and passenger mutations are associated with the malignant transformation of epithelial cells. Consequently, the book discusses recent advances in our understanding of the genetics of CRC as a biomarker, the advent of NGS technologies in modern genomics, and the impact of NGS technology on the management of CRC. Furthermore, it highlights the potential of NGS in the context of liquid biopsy and single-cell sequencing in CRC, as well as its role in shedding light on the link between gut microbiota, immune-checkpoint blockade and CRC. The book concludes with a chapter on the limitations and cost-effectiveness of NGS in CRC. Given its scope, the book will appeal to all those interested in learning about the potential of NGS in advancing CRC research and patient care.

Handbook of Gastrointestinal Cancers is a practical guide to the management of colorectal, pancreatic, hepatocellular, gastric, and esophageal cancers as well as other cancers of the upper and lower gastrointestinal tract. Edited by a multidisciplinary group of oncologists from leading institutions, this book is an essential day-to-day reference for evidence-based treatment and patient care. The handbook focuses on treatment strategies and approaches to cancerous gastrointestinal tumors that are transforming the recent oncological landscape, including expert-given guidance on methods such as neoadjuvant and adjuvant chemotherapy, surgical transplant, radiation therapy, molecular diagnostic testing leading to molecularly targeted therapy, and immunotherapy.With so many advances in the current field, it is increasingly difficult for early-career practitioners to grasp the entirety of practices and for seasoned oncologists to keep up with newly approved therapies, side effects to treatments, and special clinical management considerations, but this handbook addresses it all. Organized by major gastrointestinal disease sites and featuring “How I Treat” case vignettes from world experts for common and uncommon management considerations, the handbook brings an experience-based perspective to these tough-to-treat areas. The treatment strategies and applications set forth in the chapters are pertinent to situations and decision-making encountered in practice. Handbook of Gastrointestinal Cancers is a valuable resource for medical oncologists, radiation oncologists, and surgeons treating and managing gastrointestinal cancers as well as trainees in medical, radiation, and surgical oncology programs needing an accessible point of care resource.KEY FEATURES:Provides treatment plans and recommendations for each stage of a range of gastrointestinal cancers, including colorectal, pancreatic, and hepatocellular cancers plus moreIncludes “How I Treat” patient vignettes told from the physician's point of view within each clinical chapterOutlines special considerations for the elderly and for survivors of gastrointestinal cancersHighlights important clinical guidance on nutritional and palliative concerns commonly seen in patients with gastrointestinal cancers

Immunotherapy is a rapidly evolving field that mandates frequent revision of the book as new insights to fight cancer emerge. The third edition of Immunotherapy is an updated overview of immuno-oncology in different cancer types and toxicities associated with immunotherapy. It explores the breath of immunotherapeutic strategies available to treat a wide range of cancers, from melanoma and non-small cell lung cancer to gastrointestinal, genitourinary, gynecologic and nervous system malignancies. With increasing use of checkpoint inhibitors as standard of care and in clinical trials, the challenges associated with their use undoubtedly increase. As objective response is limited to a subset of patients and is often associated with distinct immune related side effects that are potentially life threatening, it is essential to identify patients who are likely to respond to immunotherapy and those who are at a risk for developing treatment-related side effects. In the absence of a validated predictive biomarker, innovative technologies and assays are being used to identify critical biomarkers that drive the immune response. Hence, a chapter to provide a basic understanding of the diagnostic procedures has been included besides the chapter on the cellular components of the human immune system. This new edition will also inform readers on use of novel microbiome and imaging approaches. Finally, the book includes a chapter on patient-reported outcomes in patients treated with immunotherapies as the authors recognize the importance of including missing patient voice in clinical trials and longitudinal assessment of symptom reports. In short, the third edition of this book provides a comprehensive overview of the latest developments in the field of immune-oncology that will help health care professionals make informed treatment decisions. The book's chapters are written by a diverse cast of experts conducting cutting-edge research,providing the reader with the most up-to-date science.

This book covers some well-known and some unexplored pathological aspects of management of peritoneal metastases and should be read by both surgeons and pathologists involved in the management of peritoneal surface malignancies. The evaluation of cytoreductive surgery specimens is explored for the prognostic information it can provide and recommendations for evaluation of such specimens are provided. The pathways and patterns of peritoneal dissemination and their clinical implications on the extent of surgery performed and other aspects of management are discussed for some common peritoneal tumours. The exploratory studies presented here provide a new perspective on the surgical resection of peritoneal metastases. Other important aspects of pathological evaluation like pathological response to chemotherapy, diagnosis and classification of rare peritoneal tumors have also been covered in different chapters. Keeping in sync with the progress in molecular oncology, the role ofmolecular oncology in the current and future management of peritoneal metastases is addressed for different tumors.

This book offers a comprehensive review of recent advances in cancer immunotherapy, and explores the value and limitations of the most effective current therapeutic strategies and emerging treatment modalities. It discusses in detail the successes achieved using monoclonal antibodies (mAbs), including developments with regard to conjugated mAbs and also bispecific mAbs as novel treatment options for leukemia and solid tumors. It also examines the advances toward personalized immunotherapy, focusing on the effectiveness of adoptive cell therapy using genetically engineered T cells with tumor-associated antigen-specific T-cell receptors and chimeric antigen receptors, as well as the role of tailored vaccines based on the patient's cancer mutanome. Further, it describes the impressive therapeutic results recently achieved with checkpoint inhibitors, and analyzes novel strategies to modulate the immunosuppressive tumor microenvironment. Written by leading international experts and providing up-to-date information on emerging strategies, such as oncolytic virus-based therapy, epigenetic therapy, and combination therapy, the book appeals to all those with an interest in immunotherapy as it comes of age.

This book is intended as a comprehensive resource for clinicians and researchers seeking in-depth information on geriatric oncology. The coverage encompasses epidemiology, the biology and (patho)physiology of aging and cancer, geriatric assessment and management, hematologic malignancies, solid tumors, issues in patient care, and research methods. Since cancer is a disease of aging and people are living longer, most cancer patients are now aged 70 and older. Yet the more we age, the more diverse we become in terms of our health, biologic fitness, and cancer behavior. Typically, however, general oncology clinical trials address only a selected healthier and younger population of patients. Geriatric oncology is the area of oncology that addresses these issues but while a wealth of knowledge has been accumulated, information is often difficult to retrieve or insufficiently detailed. The SpringerReference program, in which this book is published, offers an ideal format for overcoming these limitations since it combines thorough coverage with access to living editions constantly updated chapter by chapter via a dynamic peer-review process, ensuring that information remains current and pertinent.

How hype, money, and bias can mislead the public into thinking that many worthless or unproven treatments are effective.Each week, people read about new and exciting cancer drugs. Some of these drugs are truly transformative, offering major improvements in how long patients live or how they feel—but what is often missing from the popular narrative is that, far too often, these new drugs have marginal or minimal benefits. Some are even harmful. In Malignant, hematologist-oncologist Dr. Vinayak K. Prasad writes about the many sobering examples of how patients are too often failed by cancer policy and by how oncology is practiced. Throughout this work, Prasad illuminates deceptive practices which• promote novel cancer therapies long before credible data are available to support such treatment; and• exaggerate the potential benefits of new therapies, many of which cost thousands and in some cases hundreds of thousands of dollars.Prasad then critiques the financial conflicts of interest that pervade the oncology field, the pharmaceutical industry, and the US Food and Drug administration. This is a book about how the actions of human beings—our policies, our standards of evidence, and our drug regulation—incentivize the pursuit of marginal or unproven therapies at lofty and unsustainable prices. Prasad takes us through how cancer trials are conducted, how drugs come to market, and how pricing decisions are made, asking how we can ensure that more cancer drugs deliver both greater benefit and a lower price. Ultimately, Prasad says, • more cancer clinical trials should measure outcomes that actually matter to people with cancer;• patients on those trials should look more like actual global citizens;• we need drug regulators to raise, not perpetually lower, the bar for approval; and• we need unbiased patient advocates and experts.This well-written, opinionated, and engaging book explains what we can do differently to make serious and sustained progress against cancer—and how we can avoid repeating the policy and practice mistakes of the past.

This book discusses the recent developments in the therapeutic implications of cancer stem cells for the effective diagnosis, prognosis, and treatment of cancer. It summarizes the various stem cells of common cancers including colon, pancreas, lungs, prostate, melanoma, and glioblastoma, and reviews the potential role of cancer stem cells in tissue aggressiveness, examining the functional contribution of cancer stem cells in the establishment and recurrence of cancerous tumors. Further, it explores the potential of cancer stem cells as novel therapeutic targets for the treatment and prevention of tumor progression. The book also discusses the various approaches for detecting, isolating, and characterizing different cancer stem cells and signaling pathways that control their replication, survival, and differentiation. Lastly, it explores the key features and mechanisms of drug resistance, chemo-resistance, and radio-resistance in cancer stem cells to improve therapeuticrationale.

Cancer is driven by numerous genetic and epigenetic changes occurring at the cellular level. These changes drive normal cells to proliferate and escape processes that usually regulate their survival and migration. Many of these alterations are often associated with signaling pathways which regulate cell growth and division, cell death, survival, invasion and metastasis, and angiogenesis. Almost all cancer cells show high expression of signaling components including growth factor receptor tyrosine kinases (RTKs), small GTPases, serine/threonine kinases, cytoplasmic tyrosine kinases, lipid kinases, estrogen receptor, activation of transcription factors Myc and NF-κB, etc. Updated knowledge about these signaling components is highly desirable for researchers involved in developing therapies against cancer. Signal Transduction Research for Cancer Therapy covers advancements in research on the signaling pathways in the human body, especially in some types of cancers, such as breast cancer, pancreatic cancer and colon cancer. Key features of this volume include 8 focused topical reviews on signaling pathways in a specific cancer type, coverage of multiple cancer types (breast cancer, colon cancer, hepatocellular cancer, multiple myeloma, acute myeloid leukemia, and pancreatic cancer), and coverage of a wide array of signaling pathways (both receptor mediated and non receptor mediated pathways). This volume is essential reading for researchers in pharmaceutical R&D and postgraduate research programs in pharmacology and allied disciplines. Clinicians involved in oncology will also benefit from the information provided in the chapters. [Series Intro] This series provides scientists and clinicians with updated clinical information about signal transduction that will be valuable in their pursuit to investigate, develop, and apply novel agents to prevent or treat life-threatening diseases such as cancer. Contributions to the series will focus on methods that also enhance the quality of life for patients.

Publisher's Note: Products purchased from 3rd Party sellers are not guaranteed by the Publisher for quality, authenticity, or access to any online entitlements included with the product. Now updated online for the life of the edition, DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology, 11th Edition keeps you up to date in this fast-changing field. Every quarter, your eBook will be updated with late-breaking developments in oncology, including new drugs, clinical trials, and more.

Colorectal cancer is the third most commonly diagnosed condition in oncology, affecting around 1.23 million individuals per year, according to recent statistics. Of these patients, about 50% will develop liver metastases and approximately 20% will present a stage IV disease at diagnosis. These statistics make colorectal liver metastases (CLM) an issue of major importance in current oncology. The area of CLM is subject to great and continuous advances, as its pathophysiologic mechanisms are better understood and more therapeutic and surgical options are developed. Consequently, all professionals involved with the diagnosis, treatment and follow up of CLM should be kept up to date with the latest advances on the field, to provide high standard medical care to their patients. This book is designed to present the state-of-the-art in CLM management and, in doing so, to review the current evidence on CLM, discussing all important topics in the field. Coverage is broad and comprehensive, encompassing introductory topics (history, definitions, epidemiology, etc.), basic science subjects (molecular biology, genetics, dissemination process, etc.) and practical clinical topics (tumor behavior, diagnosis, drug therapy, radiation therapy, surgery, ablation, multidisciplinary teams, etc.). Although comprehensive on the coverage and selection of topics, each chapter is concise and objective, dissecting topics in a practical and direct format. Evidences and recommendations are included. Chapters display a brief introduction of the common knowledge, go straight to the detailed revision of the most recent years of the literature, and end with practical closing observations. This book is a tool for professionals (general and cancer surgeons, HPB surgeons, clinical oncologists, gastroenterologists and medical residents) and interns who search for a qualified and reader friendly revision on topics concerning Colorectal Cancer Liver Metastases.

Kidney disease and cancer are frequent comorbidities that require specialized knowledge and expertise from both the nephrologist and the oncologist. Written by three pioneers in this growing subspecialty, Onco-Nephrology provides authoritative, definitive coverage of the mechanism and management of these two life-threatening diseases. This unique, single-volume resource covers current protocols and recommends management therapies to arrest kidney failure and allow oncologic treatments to continue and succeed. - Addresses acute and chronic kidney diseases that develop from a variety of cancers. This includes direct kidney injury from the malignancy, paraneoplastic effects of the cancer, and various cancer agents used to treat the malignancy. - Discusses key issues regarding kidney disease in patients with cancer, including conventional chemotherapeutic regimens and new novel therapies (targeted agents and immunotherapies) or the malignancies themselves that may promote kidney injury; patients with chronic kidney disease who acquire cancer unrelated to renal failure; and kidney transplantation, which has been shown to carry an increased risk of cancer. - Contains dedicated chapters for each class of the conventional chemotherapeutic agents, targeted cancer agents, and cancer immunotherapies including the basic science, pathogenic mechanisms of injury, clinical manifestations, and treatment. - Includes special chapters devoted to the individual classes of chemotherapies that relate to kidney disease for quick reference. Discusses increasingly complex problems due to more numerous and specialized anti-cancer drugs, as well as increased survival rates for both cancer and renal failure requiring long-term patient care. - Covers anti-VEGF (antivascular endothelial growth factor) agents and cancer immunotherapies – treatments that are being recognized for adverse kidney effects. - Utilizes a clear, logical format based on the ASN Core Curriculum for Onco-Nephrology, making this reference an excellent tool for board review, as well as a practical resource in daily practice. - Enhanced eBook version included with purchase. Your enhanced eBook allows you to access all of the text, figures, and references from the book on a variety of devices.

This book presents the latest advances in precision medicine in some of the most common cancer types, including hematological, lung and breast malignancies. It also discusses emerging technologies that are making a significant impact on precision medicine in cancer therapy. In addition to describing specific approaches that have already entered clinical practice, the book explores new concepts and tools that are being developed.Precision medicine aims to deliver personalized healthcare tailored to a patient's genetics, lifestyle and environment, and cancer therapy is one of the areas in which it has flourished in recent years. Documenting the latest advances, this book is of interest to physicians and clinical fellows in the front line of the war on cancer, as well as to basic scientists working in the fields of cancer biology, drug development, biomarker discovery, and biomedical engineering. The contributing authors include translational physicians withfirst-hand experience in precision patient care.

Colorectal cancer (CRC) is a leading cause of cancer-related death worldwide. Recent years have increased significantly our understanding of the genetic alterations that can underlie CRC, but also unraveled the molecular heterogeneity of the disease. Although a simple correlation between genetic pathways, histopathological features and clinical outcome cannot be established, the heterogeneity of CRC is also an opportunity for the development of targeted therapeutic approaches, able to treat an individual tumor with higher efficiency and less toxic side effects. One CRC subtype is characterized by high mutation rates (MSI-H), DNA methylation changes (CIMP-H), mutation in the BRAF oncogene and occurrence of serrated adenomas in the proximal colon. Other groups prevail in the distal colon and consist of either adenomatous polyps with chromosomal aberrations (CIN) and WNT pathway activation, or carry frequent KRAS mutation and metabolic deregulation, or have strong mesenchymal andinfiltrative characteristics. Characterization of driver-mutation events in these CRC subgroups has led to the development of specific drugs targeting, for example, the MAPK pathway, but initial clinical trials have revealed unexpected response rates. The collection of chapters in this volume address the biology of specific CRC subtypes and how these may be targeted to improve precision therapy and clinical benefit for the patients.

This textbook discusses core principles and practices in gastrointestinal oncology and covers a wide range of practice areas such as pathology and radiologic images, epidemiology, genetics, staging, multidisciplinary management of specific gastrointestinal cancer, and pathology for each primary tumor site. The comprehensive coverage makes Textbook of Gastrointestinal Oncology a useful resource for the practitioner wishing to gain a greater understanding of the principles of managing malignant gastrointestinal disease, as well as medical oncology fellows, surgeons, radiation oncologists, gastroenterologists and fellows, and residents.

This book elaborates on drug delivery targeting via intracellular delivery, specifically through the Receptor Mediated Endocytosis (RME) approach, due to the involvement of cellular receptors in various grave diseases. Targeted delivery relies on two basic approaches, passive and active targeting. While passive targeting approaches have shown great promise, the improved selectivity achieved with active targeting approaches has resulted in significantly higher efficacy. Interestingly there are numerous strategies for active targeting, many of which are already highlighted in, Targeted Drug Delivery: Concepts and Applications. Nevertheless an exciting and practical strategy for active targeting, which could enable high intracellular delivery, is through exploitation of RME. Cells in the body express receptors to enable various physiological and biochemical processes. As a result, many of these receptors are overexpressed in pathological conditions, or newer receptors expressed due to defective cellular functioning. RME is based on exploitation of such receptors to achieve intracellular delivery. While targeted delivery can have manifold applications, in this book we focus on two major and challenging therapeutic areas; i) Cancer and ii) Infectious Diseases. Targeted Intracellular Drug Delivery by Receptor Medicated Endocytosis discusses the major receptors that are useful for targeted delivery for these afflictions. A major section of this book is dedicated to details regarding their occurrence and location, the recognition domain of the receptor, structure activity relationship of substrate /ligand for selective binding, ligands explored, antagonists for ligand binding and relevance of these aspects for therapy of cancer and infectious diseases. These facets are elucidated with the help of specific examples from academic research and also emphasize commercial products, wherever relevant. In vitro cellular models relied onfor assessing receptor mediated cellular targeting and in vivo models depicting clinical efficacy are focused on in a separate section. Finally, we briefly discuss the regulatory and toxicity issues that may be associated specifically with the RME approach of intracellular drug delivery.

This exhaustive work shows that new therapies using anti-angiogenic drugs are of particular importance because they can be used against many different types of cancer, as tumor angiogenesis seems to be involved in most if not all solid metastasizing malignancies. The first part of this book summarizes the knowledge acquired on the molecular entities that play a role in tumor angiogenesis and their mechanisms of action. Furthermore, the identification of molecular markers and their validation as predictive and/or prognostic tools is reviewed. In the second and most important part, the clinical applications of anti-angiogenic treatments are documented for a wide variety of tumors. In particular, the modes of combination with other targeted and/or cytotoxic cancer therapies are presented.​

This authoritative work, now in its fourth edition, presents state of the art knowledge on all key aspects of cancer prevention. In addition to detailed summaries on preventive strategies for specific cancers, readers will find current knowledge on a range of relevant scientific topics including the benefits of cancer prevention, the importance of diet and physical activity, innate and adaptive immune responses to cancer, hereditary risks, cancer health disparities, and the preventive role of telemedicine. In this new edition of the book, the coverage has been expanded to include additional disease sites and to provide up-to-date information across the range of disciplines in the field of cancer prevention and control. Written as a collaborative work by internationally recognized leaders in the field, Fundamentals of Cancer Prevention is an essential reference guide and tool for oncologists, primary care physicians, the research community, and students with an interest in reducing the burden of cancer through the implementation of effective preventive strategies.